Tao Shang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tao Shang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Leilei Wang
C Department of Obstetrics and Gynaecology , Shengjing Hospital of China Medical University , Shenyang , China
2 shared publicationsLihua Fu
B Department of Obstetrics and Gynaecology , Ditan Hospital Capital Medical University , Beijing , China
2 shared publicationsChong Qiao
Department of Obstetrics and Gynaecology, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publicationDan Zhang
Department of Obstetrics and Gynaecology, Shengjing Hospital of China Medical University, Shenyang, China
1 shared publication- Dan Zhang
Shenyang Clinical Medical Research Center for Obstetrics and Gynecology, Shenyang Women’s and Children’s Hospital, 110011 Shenyang, Liaoning, China
1 shared publication Lihong Yu
A Department of Obstetrics and Gynaecology , Shenyang Women's and Children's Hospital , Shenyang , China
1 shared publication
Latest Publications
- 13 June 2017
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 36 (3) , 247-258
Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection
Immunomodulation by mesenchymal stem cells (MSCs) is potentially important for maintaining peripheral tolerance. Preeclampsia may be due to maternal immune rejection of the genetically foreign fetus. This study aimed to investigate the biological function of human umbilical cord–derived mesenchymal stem cells (HU-MSCs) for the treatment of angiotensin receptor agonistic autoantibody (AT1-AA)-induced hypertension during pregnancy. HU-MSCs were isolated, cultured, and labeled in vitro. AT1-AA and HU-MSCs were administered to pregnant rats. Green fluorescent protein (GFP)–positive HU-MSCs infused in vivo were identified by immunofluorescence. Systolic blood pressure (SBP) was evaluated. The effects of HU-MSCs on fetal weight, kidney burden, and spiral artery remodeling, as well as on the expression of tumor necrosis factor α (TNF-α), interleukin 10 (IL-10), and heme oxygenase 1 (HO-1), were investigated. The SBP levels in the HU-MSC-treated pregnant hypertension rats decreased by gestational day 19. The reduction in fetal weight was largely ameliorated after HU-MSC treatment. Lesion burden in the kidney was attenuated and spiral artery remodeling was improved in HU-MSC-treated pregnant hypertension rats. However, green fluorescent protein (GFP)–labeled cells were sparingly observed in the kidney and placenta. Intravenous infusion of HU-MSCs into AT1-AA-induced rats significantly downregulated serum TNF-α levels and upregulated IL-10 levels, concomitant with increased placenta and mesometrial triangle (MT) HO-1 expression. Taken together, intravenous infusion of HU-MSCs ameliorates AT1-AA-induced pregnancy hypertension, intrauterine growth retardation, kidney impairment, and spiral artery remodeling impairment. Moreover, the potential benefits of HU-MSCs may be attributable to both an interference with the pathogenic immune response and a paracrine cytoprotective action.
- 13 June 2017
- Published by Taylor & Francis in Hypertension in Pregnancy
- Vol. 36 (3) , 247-258
Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection
Immunomodulation by mesenchymal stem cells (MSCs) is potentially important for maintaining peripheral tolerance. Preeclampsia may be due to maternal immune rejection of the genetically foreign fetus. This study aimed to investigate the biological function of human umbilical cord–derived mesenchymal stem cells (HU-MSCs) for the treatment of angiotensin receptor agonistic autoantibody (AT1-AA)-induced hypertension during pregnancy. HU-MSCs were isolated, cultured, and labeled in vitro. AT1-AA and HU-MSCs were administered to pregnant rats. Green fluorescent protein (GFP)–positive HU-MSCs infused in vivo were identified by immunofluorescence. Systolic blood pressure (SBP) was evaluated. The effects of HU-MSCs on fetal weight, kidney burden, and spiral artery remodeling, as well as on the expression of tumor necrosis factor α (TNF-α), interleukin 10 (IL-10), and heme oxygenase 1 (HO-1), were investigated. The SBP levels in the HU-MSC-treated pregnant hypertension rats decreased by gestational day 19. The reduction in fetal weight was largely ameliorated after HU-MSC treatment. Lesion burden in the kidney was attenuated and spiral artery remodeling was improved in HU-MSC-treated pregnant hypertension rats. However, green fluorescent protein (GFP)–labeled cells were sparingly observed in the kidney and placenta. Intravenous infusion of HU-MSCs into AT1-AA-induced rats significantly downregulated serum TNF-α levels and upregulated IL-10 levels, concomitant with increased placenta and mesometrial triangle (MT) HO-1 expression. Taken together, intravenous infusion of HU-MSCs ameliorates AT1-AA-induced pregnancy hypertension, intrauterine growth retardation, kidney impairment, and spiral artery remodeling impairment. Moreover, the potential benefits of HU-MSCs may be attributable to both an interference with the pathogenic immune response and a paracrine cytoprotective action.
- 28 May 2014
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 31 (10) , 883-890
The Role of the Reduction of Spiral Artery Remodeling and Heme Oxygenase 1 in Mediating AT1-AA–Induced Hypertension and Intrauterine Growth Restriction in Pregnant Rats
Introduction: Recently, emerging evidence has indicated that preeclamptic women who have angiotensin receptor agonistic autoantibodies (AT1-AA), these antibodies contribute to features of the disease. Aim: The purpose of this study was to determine the role of spiral artery remodeling in mediating AT1-AA–induced hypertension and intrauterine growth restriction in pregnant rats. We hypothesized that AT1-AA–mediated heme oxygenase 1 (HO-1) reduction contributes to decreased spiral artery remodeling. Rat AT1-AA and an HO-1 inducer were administered to pregnant rats. Result: Mean arterial pressure (MAP) increased from 98 ± 4 mm Hg in normal pregnant rats to 113 ± 6 mm Hg in AT1-AA–infused rats (p < 0.05), which was significantly attenuated by the HO-1 inducer (103 ± 2 mm Hg). Fetal weight was also attenuated by HO-1 inducer, and kidney and liver development was adversely affected. Spiral artery remodeling was significantly reduced in AT1-AA-treated pregnant rats compared with that in normal pregnant rats, and this was significantly ameliorated by an HO-1 inducer. Conclusion: Our findings demonstrate that AT1-AA-mediated HO-1 reduction contributes to reduced spiral artery remodeling, and is one mechanism whereby AT1-AA mediates hypertension and intrauterine growth retardation.
- 28 May 2014
- Published by Georg Thieme Verlag KG in American Journal of Perinatology
- Vol. 31 (10) , 883-890
The Role of the Reduction of Spiral Artery Remodeling and Heme Oxygenase 1 in Mediating AT1-AA–Induced Hypertension and Intrauterine Growth Restriction in Pregnant Rats
Introduction: Recently, emerging evidence has indicated that preeclamptic women who have angiotensin receptor agonistic autoantibodies (AT1-AA), these antibodies contribute to features of the disease. Aim: The purpose of this study was to determine the role of spiral artery remodeling in mediating AT1-AA–induced hypertension and intrauterine growth restriction in pregnant rats. We hypothesized that AT1-AA–mediated heme oxygenase 1 (HO-1) reduction contributes to decreased spiral artery remodeling. Rat AT1-AA and an HO-1 inducer were administered to pregnant rats. Result: Mean arterial pressure (MAP) increased from 98 ± 4 mm Hg in normal pregnant rats to 113 ± 6 mm Hg in AT1-AA–infused rats (p < 0.05), which was significantly attenuated by the HO-1 inducer (103 ± 2 mm Hg). Fetal weight was also attenuated by HO-1 inducer, and kidney and liver development was adversely affected. Spiral artery remodeling was significantly reduced in AT1-AA-treated pregnant rats compared with that in normal pregnant rats, and this was significantly ameliorated by an HO-1 inducer. Conclusion: Our findings demonstrate that AT1-AA-mediated HO-1 reduction contributes to reduced spiral artery remodeling, and is one mechanism whereby AT1-AA mediates hypertension and intrauterine growth retardation.